ArticleBlood cancer journal2024

Calr type 1/like mutation in myelofibrosis is the most prominent predictor of momelotinib drug survival and longevity without transplant.

Ayalew Tefferi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.